FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileViatris Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
VTRS
Viatris Inc. Stock AnalysisComprehensive stock analysis for Viatris Inc. (VTRS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisVTRS
VTRS
Viatris Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
VTRS
  1. Home
  2. Stocks
  3. Viatris Inc.

Viatris Inc.

🇺🇸VTRS•NASDAQ

Viatris Inc.

🇺🇸VTRS•NASDAQ
Market cap
$23.78B
Sentiment

Your view on VTRS

Mkt Cap
$23.78B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Viatris Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Scott Andrew Smith
Headquarters
1000 Mylan Boulevard, Canonsburg, PA, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Scott Andrew Smith
Headquarters
1000 Mylan Boulevard, Canonsburg, PA, US
Description

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).

The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.

It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.

The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.

It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE.

The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Viatris Inc. from FRC's valuation model, read against the market price. VTRS last traded at $20.74; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Viatris Inc.. Starting points for Viatris Inc.: EPS -$0.53, beta 0.87 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Viatris Inc.. Viatris Inc. paid $0.48 per share over the last year — a 2.3% yield at the current $20.74 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Viatris Inc.. Trailing twelve-month EPS for Viatris Inc. stands at -$0.53. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$21.00

average of 9 firms, last 12 months

 

$21.00

Low $14.00

Median $20.00

High $26.00

 

Analyst Ratings

Buy6 firms, last 12 months
  • Strong Buy0
  • Buy4
  • Hold2
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.61$0.63$2.58$2.77
Low estimate$0.58$0.59$2.52$2.64
High estimate$0.64$0.67$2.62$2.90
No. of analysts6466
Year-ago EPS$0.57$0.59-$3.001—
Growth+6.5%+6.8%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$3.76B$3.63B$14.80B$15.36B
Low estimate$3.73B$3.50B$14.74B$14.87B
High estimate$3.81B$3.70B$14.82B$15.77B
No. of analysts6476
Year-ago revenue$3.70B$3.52B$14.30B—
Growth+1.6%+3.1%+3.5%—
Recent analyst actions15 rating and price-target changes, latest Nov 6, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Viatris Inc.. Viatris Inc. has reported as a listed company since 1980. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold VTRS19 companies · 8 funds
Compare VTRS with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ALKSAlkermes plcDrug Manufacturers - Specialty & Generic$7.8B
  • AMPHAmphastar Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$1.2B
  • AMRXAmneal Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$7.4B
  • ANIPANI Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$1.6B
  • BHCBausch Health Companies Inc.Drug Manufacturers - Specialty & Generic$3.2B
  • HLNHaleon plcDrug Manufacturers - Specialty & Generic$40.4B
  • OGNOrganon & Co.Drug Manufacturers - General$3.7B

More Drug Manufacturers - Specialty & Generic companies

  • INLBItem 9 Labs Corp.OTC$70,181
  • INMInMed Pharmaceuticals Inc.NASDAQ$9M
  • INSDInstadose Pharma Corp.OTC$53,193
  • IONKFIonic Brands Corp.OTC$1,592
  • IPSEFIpsen S.A.OTC$9.4B
  • IPSEYIpsen S.A.OTC$61.0B
  • IRWDIronwood Pharmaceuticals, Inc.NASDAQ$803M
  • ISCNFIsracann Biosciences Inc.OTC$1,982
  • ISOLFIsodiol International Inc.OTC$4,914
  • ITHUFiAnthus Capital Holdings, Inc.OTC$34M
  • IVIXFInvion LimitedOTC$3M
  • IVX.AXInvion LimitedASX

ETFs holding Viatris Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.03%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.03%
  • VBVanguard Small-Cap ETF$76.9B in assets0.27%
  • VBRVanguard Small-Cap Value ETF$35.1B in assets0.47%
  • ADPVAdaptiv Select ETF$173M in assets5.97%
  • DUSADavis Select U.S. Equity ETF$1.3B in assets5.48%
  • IHEiShares US Pharmaceuticals ETF$1.7B in assets4.88%
  • FTXHFirst Trust Nasdaq Pharmaceuticals ETF$1.2B in assets4.23%

Largest holders first, then the funds most concentrated in VTRS.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Viatris Inc., and how their positions are changing. At a $23.78B market value, institutional positions materially move Viatris Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Viatris Inc. executives and directors. Shares of Viatris Inc. have traded between $6.85 and $13.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Viatris Inc.. Viatris Inc. is a $23.78B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Viatris Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Viatris Inc.. Coverage tracks Viatris Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Viatris Inc.

VTRS Analysis
Fair
Past5
Growth1
Health3
Profit1
Value1

News

Latest Market News